BR112023002129A2 - Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma - Google Patents
Composição farmacêutica de inibidor de aquaporina e método de preparação da mesmaInfo
- Publication number
- BR112023002129A2 BR112023002129A2 BR112023002129A BR112023002129A BR112023002129A2 BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2 BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A BR112023002129 A BR 112023002129A BR 112023002129 A2 BR112023002129 A2 BR 112023002129A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- preparing
- same
- aquaporin
- aquaporin inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010779964 | 2020-08-05 | ||
| PCT/CN2021/110506 WO2022028459A1 (en) | 2020-08-05 | 2021-08-04 | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002129A2 true BR112023002129A2 (pt) | 2023-04-18 |
Family
ID=80120008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002129A BR112023002129A2 (pt) | 2020-08-05 | 2021-08-04 | Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma |
Country Status (12)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602682B (zh) | 2012-05-08 | 2018-12-14 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| EP3065729A4 (en) | 2013-11-06 | 2017-05-31 | Aeromics, Inc. | Novel formulations |
| AU2017261828B2 (en) | 2016-05-13 | 2023-04-13 | Aeromics, Inc. | Crystals |
| WO2024208207A1 (zh) * | 2023-04-03 | 2024-10-10 | 拜西欧斯(北京)生物技术有限公司 | 一种双取代萘化合物及其药物组合物和用途 |
| WO2025075479A1 (ko) * | 2023-10-04 | 2025-04-10 | 이화여자대학교 산학협력단 | 아쿠아포린 4 억제제의 심방세동 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7626042B2 (en) * | 2002-06-06 | 2009-12-01 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| US9316633B2 (en) * | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| CN104602682B (zh) | 2012-05-08 | 2018-12-14 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| EP3065729A4 (en) | 2013-11-06 | 2017-05-31 | Aeromics, Inc. | Novel formulations |
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2017261828B2 (en) * | 2016-05-13 | 2023-04-13 | Aeromics, Inc. | Crystals |
-
2021
- 2021-08-04 BR BR112023002129A patent/BR112023002129A2/pt unknown
- 2021-08-04 KR KR1020237007248A patent/KR20230137284A/ko active Pending
- 2021-08-04 EP EP21852147.4A patent/EP4192442A4/en active Pending
- 2021-08-04 JP JP2023508083A patent/JP7877294B2/ja active Active
- 2021-08-04 WO PCT/CN2021/110506 patent/WO2022028459A1/en not_active Ceased
- 2021-08-04 CN CN202180057413.1A patent/CN117337182A/zh active Pending
- 2021-08-04 MX MX2023001493A patent/MX2023001493A/es unknown
- 2021-08-04 AU AU2021323181A patent/AU2021323181A1/en active Pending
- 2021-08-04 IL IL300341A patent/IL300341A/en unknown
- 2021-08-04 US US18/040,618 patent/US20230293556A1/en active Pending
- 2021-08-04 CA CA3187716A patent/CA3187716A1/en active Pending
- 2021-08-05 TW TW110128921A patent/TW202228714A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192442A1 (en) | 2023-06-14 |
| TW202228714A (zh) | 2022-08-01 |
| MX2023001493A (es) | 2023-06-23 |
| WO2022028459A1 (en) | 2022-02-10 |
| US20230293556A1 (en) | 2023-09-21 |
| JP7877294B2 (ja) | 2026-06-22 |
| JP2023536509A (ja) | 2023-08-25 |
| KR20230137284A (ko) | 2023-10-04 |
| IL300341A (en) | 2023-04-01 |
| CN117337182A (zh) | 2024-01-02 |
| AU2021323181A1 (en) | 2023-03-23 |
| EP4192442A4 (en) | 2025-03-19 |
| CA3187716A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001493A (es) | Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. | |
| BR112023021383A2 (pt) | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo | |
| EP4595965A3 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| Hendriks et al. | Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities | |
| EP1158985A1 (en) | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | |
| BRPI0213570B8 (pt) | cristal na forma alfa de acetanilida e composição farmacêutica sólida que a compreende | |
| US20120149706A1 (en) | Inhibition of p38 kinase activity using substituted heterocyclic ureas | |
| UA104471C2 (uk) | ФАРМАЦЕВТИЧНА ДОЗОВАНА ФОРМА ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ ІНГІБІТОРУ СІМЕЙСТВА Bcl-2 | |
| BRPI0409227A (pt) | composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto | |
| WO1999032111A1 (en) | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| DE10017480A1 (de) | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren | |
| JP2025507472A5 (cg-RX-API-DMAC10.html) | ||
| MX2025008424A (es) | Formulacion de lanifibranor | |
| MX2024008371A (es) | Compuestos organicos deuterados y usos de los mismos | |
| AR133698A1 (es) | COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS | |
| BR112023025221A2 (pt) | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos | |
| MX2022007176A (es) | 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina. | |
| WO2023150790A3 (en) | Novel and highly selective sars-cov-2 mpro inhibitors | |
| MX2025010949A (es) | Derivados de ciclohexanona fusionados con tiofeno sustituido, composiciones que comprenden los mismos y su uso como productos farmacéuticos | |
| ES2396764B1 (es) | FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
| MX2023001742A (es) | Agente terapeutico para la enfermedad de higado graso. | |
| AR046143A1 (es) | Composicion farmaceutica que contiene un derivado de tiourea con solubilidad y biodisponiblidad mejoradas | |
| BR112021014881A2 (pt) | Composto de poliol anti-hipertensivo e derivados do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |